Biotect/Life Science Investments
At Mint12 Pharma, we are passionate about investing in biotech innovation. We believe in the transformative power of life-changing sciences and are committed to supporting dynamic companies at the forefront of this field.
Investing in biotech innovation can be challenging, but we have the expertise and experience to navigate this complex field. Our team of experts includes seasoned professionals with deep expertise in biotech and life sciences who bring a wealth of knowledge and insights to our investment decisions.
Our Strategy
Our investment strategy involves partnering with companies with a proven track record of developing groundbreaking technologies and products. We provide them with the resources and support they need to achieve their goals, with a focus on creating long-term value for our investors and contributing to the advancement of life-changing technologies and products that benefit society.
At MINT12 Pharma, we are committed to investing in companies that have the potential to create significant value for our investors while also making a positive impact on society. We are passionate about supporting companies developing innovative solutions to the world's most pressing medical challenges, from new treatments for severe diseases to cutting-edge medical technologies.
Dr. Kurt Gehlsen
Chief Science Officer MINT12 Pharma
Dr. Gehlsen has over 35 years of experience in basic research, pharmaceutical and medical device product development, clinical development, regulatory affairs, investment, company formation, and executive management.
Before joining MINT12 Pharma, Dr. Gehlsen was Vice President and Chief Scientific Officer (CSO) at Research Corporation Technologies, Inc. (RCT). RCT is an early-stage venture investment and development company with over 600 million dollars in AUM. Dr. Gehlsen provided scientific direction for RCT’s development and investment activities and had direct responsibility for diligence, investments, licensing, and managing internal projects in therapeutics, diagnostics, research tools, and medical devices. In addition, he was responsible for Abdurin Platform, Sarcin Platform, Pichia GlycoSwitch Platform, Yeast Display Platform, Pichia licensing program, GM-CSF (Amgen, Sanofi), Herpes Zoster Vaccine (GSK); managed more than 400 licenses and more than 20 milliopn dollars in annual royalties from licensed programs. Further, he had strategic roles in Spirogen, Femtogenix, Jenrin, Esperance, Dispersol, BroadOak, and Option 3. Dr. Gehlse’s programs have a forecasted distributed to paid-in capital of 71.6x .
Prior to RCT, Dr. Gehlsen was Senior Vice President, Development, and Chief Scientific Officer at Maxim Pharmaceuticals. This public biopharmaceutical company developed and launched CepleneTM the first immune counter-suppression therapeutic, as a remission maintenance therapy for Acute myeloid leukemia. Before Maxim, Dr. Gehlsen was the founder and CEO of Trauma Products, which developed and launched RescueFlowTM, a small-volume resuscitation solution for life-threatening trauma. He also was Director of Research in the Experimental Medicine Division of Pharmacia, AB., Uppsala, Sweden, and La Jolla, CA. He was a Postdoctoral Fellow and Research Associate at the Sanford Prebys Burnham Institute.
Dr. Gehlsen’s academic experience focused primarily on cancer research. He held positions as an Associate Professor at the Sidney Kimmel Cancer Center in La Jolla, as an Associate Staff Scientist at the California Institute for Biological Research in La Jolla, and as Founder, Vice President, and Chief Operating Officer at the La Jolla Institute for Experimental Medicine in La Jolla. Dr. Gehlsen has published over 140 manuscripts, book chapters, and meeting abstracts and has filed over 100 patents and patent applications.
Dr. Gehlsen received his Bachelor of Science degree in Civil Engineering and General Biology, with minors in math, chemistry, and physics, from the University of Arizona and his Doctoral degree from the University of Arizona College of Medicine.
Current Portfolio
PleoPharma
PleoPharma, Inc. was founded in 2019 by two physicians, Ginger Constantine and Jay Constantine, one of whom worked to develop new medications and the other as a practicing clinician.
The idea for Pleopharma was spawned when the founders observed several individuals within a short period of time Read More
Myosin Therapeutics
Myosin Therapeutics is a privately-held biopharmaceutical company developing novel medications targeting cellular motor proteins, specialized molecular machines that convert energy into mechanical work inside cells. Molecular motors are an under-exploited area of disease treatment, including cancer.